Emmad Qazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emmad Qazi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Michael Douglas Hill
Department of Clinical Neurosciences, University of Calgary, Canada (M.D.H.).
3 shared publications - Andrew Michael Demchuk
Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada (A.M.D.).
2 shared publications - Bijoy K. Menon
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
2 shared publications - Lydia D. Foster
Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
2 shared publications - Mayank Goyal
University of Calgary
2 shared publications - Sharon D. Yeatts
Medical University of South Carolina
2 shared publications
Latest Publications
- 6 June 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (7) , 943-952
Operator Intracranial Dose Protection During Fluoroscopic-Guided Interventions
Purpose We utilized an anthropomorphic model made with a human skull to determine how different personal protective equipment influence operator intracranial radiation absorbed dose. Materials and Methods A custom anthropomorphic phantom made with a human skull coated with polyurethane rubber, mimicking superficial tissues, and was mounted onto a plastic thorax. To simulate scatter, an acrylic plastic scatter phantom was placed onto the fluoroscopic table with a 1.5 mm lead apron on top. Two Radcal radiation detectors were utilized; one inside of the skull and a second outside. Fluoroscopic exposures were performed with and without radiation protective equipment in AP, 45-degree RAO, and 45-degree LAO projections. Results The skull and soft tissues reduce intracranial radiation by 76% when compared to radiation outside the skull. LAO (308.95 μSv/min) and RAO projections (96.47μSv/min) result in significantly higher radiation exposure to the primary operator when compared to an AP projection (54 μSv/min). All tested radiation protection equipment demonstrated various reduction in intracranial radiation when compared to no protection. The hood (68% reduction in AP, 91% LAO, and 43% in RAO), full cover (53% reduction in AP, 76% in LAO, and 54% in RAO), and open top with ear coverage (43% reduction in AP, 77% reduction in LAO, and 22% in RAO) demonstrated the most reduction in intracranial radiation when compared to the control. Conclusion All tested equipment provided various degrees of additional intracranial protection. The skull and soft tissues attenuate a portion of intracranial radiation.
- 6 June 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 46 (7) , 943-952
Operator Intracranial Dose Protection During Fluoroscopic-Guided Interventions
Purpose We utilized an anthropomorphic model made with a human skull to determine how different personal protective equipment influence operator intracranial radiation absorbed dose. Materials and Methods A custom anthropomorphic phantom made with a human skull coated with polyurethane rubber, mimicking superficial tissues, and was mounted onto a plastic thorax. To simulate scatter, an acrylic plastic scatter phantom was placed onto the fluoroscopic table with a 1.5 mm lead apron on top. Two Radcal radiation detectors were utilized; one inside of the skull and a second outside. Fluoroscopic exposures were performed with and without radiation protective equipment in AP, 45-degree RAO, and 45-degree LAO projections. Results The skull and soft tissues reduce intracranial radiation by 76% when compared to radiation outside the skull. LAO (308.95 μSv/min) and RAO projections (96.47μSv/min) result in significantly higher radiation exposure to the primary operator when compared to an AP projection (54 μSv/min). All tested radiation protection equipment demonstrated various reduction in intracranial radiation when compared to no protection. The hood (68% reduction in AP, 91% LAO, and 43% in RAO), full cover (53% reduction in AP, 76% in LAO, and 54% in RAO), and open top with ear coverage (43% reduction in AP, 77% reduction in LAO, and 22% in RAO) demonstrated the most reduction in intracranial radiation when compared to the control. Conclusion All tested equipment provided various degrees of additional intracranial protection. The skull and soft tissues attenuate a portion of intracranial radiation.
- Open Access
- 2 July 2020
- Published by SAGE Publications in Canadian Association of Radiologists Journal
- Vol. 72 (1) , 180-182
COVID-19 Pandemic on Canadian Radiology Residency Education—Impact and Solutions: University of Toronto Perspective
- 2 July 2020
- Published by SAGE Publications in Canadian Association of Radiologists Journal
- Vol. 72 (1) , 180-182
Open AccessCOVID-19 Pandemic on Canadian Radiology Residency Education—Impact and Solutions: University of Toronto Perspective
- Open Access
- 17 March 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (8) , 1393-1398
Multimodal CT Imaging: Time to Treatment and Outcomes in the IMS III Trial
BACKGROUND AND PURPOSE: The importance of time in acute stroke is well-established. Using the Interventional Management of Stroke III trial data, we explored the effect of multimodal imaging (CT perfusion and/or CT angiography) versus noncontrast CT alone on time to treatment and outcomes. MATERIALS AND METHODS: We examined 3 groups: 1) subjects with baseline CTP and CTA (CTP+CTA), 2) subjects with baseline CTA without CTP (CTA), and 3) subjects with noncontrast head CT alone. The demographics, treatment time intervals, and clinical outcomes in these groups were studied. RESULTS: Of 656 subjects enrolled in the Interventional Management of Stroke III trial, 90 (13.7%) received CTP and CTA, 216 (32.9%) received CTA (without CTP), and 342 (52.1%) received NCCT alone. Median times for the CTP+CTA, CTA, and NCCT groups were as follows: stroke onset to IV tPA (120.5 versus 117.5 versus 120 minutes; P = .5762), IV tPA to groin puncture (77.5 versus 81 versus 91 minutes; P = .0043), groin puncture to endovascular therapy start (30 versus 38 versus 44 minutes; P = .0001), and endovascular therapy start to end (63 versus 46 versus 74 minutes; P < .0001). Compared with NCCT, the CTA group had better outcomes in the endovascular arm (OR, 2.12; 95% CI, 1.36–3.31; adjusted for age, NIHSS score, and time from onset to IV tPA). The CTP+CTA group did not have better outcomes compared with the NCCT group. CONCLUSIONS: Use of CTA with or without CTP did not delay IV tPA or endovascular therapy compared with NCCT in the Interventional Management of Stroke III trial.
- 17 March 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (8) , 1393-1398
Open AccessMultimodal CT Imaging: Time to Treatment and Outcomes in the IMS III Trial
BACKGROUND AND PURPOSE: The importance of time in acute stroke is well-established. Using the Interventional Management of Stroke III trial data, we explored the effect of multimodal imaging (CT perfusion and/or CT angiography) versus noncontrast CT alone on time to treatment and outcomes. MATERIALS AND METHODS: We examined 3 groups: 1) subjects with baseline CTP and CTA (CTP+CTA), 2) subjects with baseline CTA without CTP (CTA), and 3) subjects with noncontrast head CT alone. The demographics, treatment time intervals, and clinical outcomes in these groups were studied. RESULTS: Of 656 subjects enrolled in the Interventional Management of Stroke III trial, 90 (13.7%) received CTP and CTA, 216 (32.9%) received CTA (without CTP), and 342 (52.1%) received NCCT alone. Median times for the CTP+CTA, CTA, and NCCT groups were as follows: stroke onset to IV tPA (120.5 versus 117.5 versus 120 minutes; P = .5762), IV tPA to groin puncture (77.5 versus 81 versus 91 minutes; P = .0043), groin puncture to endovascular therapy start (30 versus 38 versus 44 minutes; P = .0001), and endovascular therapy start to end (63 versus 46 versus 74 minutes; P < .0001). Compared with NCCT, the CTA group had better outcomes in the endovascular arm (OR, 2.12; 95% CI, 1.36–3.31; adjusted for age, NIHSS score, and time from onset to IV tPA). The CTP+CTA group did not have better outcomes compared with the NCCT group. CONCLUSIONS: Use of CTA with or without CTP did not delay IV tPA or endovascular therapy compared with NCCT in the Interventional Management of Stroke III trial.
- Open Access
- 30 July 2015
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 36 (11) , 2134-2139
Carotid Webs and Recurrent Ischemic Strokes in the Era of CT Angiography
BACKGROUND AND PURPOSE: Carotid webs may cause recurrent ischemic stroke. We describe the prevalence, demographics, clinical presentation, imaging features, histopathology, and stroke risk associated with this under-recognized lesion. MATERIALS AND METHODS: A carotid web was defined on CTA as a thin intraluminal filling defect along the posterior wall of the carotid bulb just beyond the carotid bifurcation on oblique sagittal section CTA that was seen as a septum on axial CTA. Using a prospective case series from April 2013 to April 2014, we describe the demographics, spectrum of imaging features on CTA, and histopathology of these carotid webs. From a retrospective analysis of patients at our center from May 2012 to April 2013 who had a baseline head and neck CTA followed by a brain MR imaging within 1–2 days of the CTA, we determine the period prevalence of carotid webs and the prevalence of ipsilateral stroke on imaging. RESULTS: In the prospective series, the mean age was 50 years (range, 41–55 years); 5/7 patients were women. Recurrent stroke was seen in 5/7 (71.4%) patients with the carotid web; time to recurrence ranged from 1 to 97 months. Histopathology suggested a high probability of fibromuscular dysplasia. In the retrospective series, carotid webs were seen in 7/576 patients for a hospital-based-period prevalence of 1.2% (95% CI, 0.4%–2.5%). Two of these 7 patients had acute stroke in the vascular territory of the carotid web. CONCLUSIONS: A carotid web may contribute to recurrent ischemic stroke in patients with no other determined stroke mechanism. Intimal variant fibromuscular dysplasia is the pathologic diagnosis in most cases. The prevalence of carotid web is low, while the optimal management strategy remains unknown.
- 30 July 2015
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 36 (11) , 2134-2139
Open AccessCarotid Webs and Recurrent Ischemic Strokes in the Era of CT Angiography
BACKGROUND AND PURPOSE: Carotid webs may cause recurrent ischemic stroke. We describe the prevalence, demographics, clinical presentation, imaging features, histopathology, and stroke risk associated with this under-recognized lesion. MATERIALS AND METHODS: A carotid web was defined on CTA as a thin intraluminal filling defect along the posterior wall of the carotid bulb just beyond the carotid bifurcation on oblique sagittal section CTA that was seen as a septum on axial CTA. Using a prospective case series from April 2013 to April 2014, we describe the demographics, spectrum of imaging features on CTA, and histopathology of these carotid webs. From a retrospective analysis of patients at our center from May 2012 to April 2013 who had a baseline head and neck CTA followed by a brain MR imaging within 1–2 days of the CTA, we determine the period prevalence of carotid webs and the prevalence of ipsilateral stroke on imaging. RESULTS: In the prospective series, the mean age was 50 years (range, 41–55 years); 5/7 patients were women. Recurrent stroke was seen in 5/7 (71.4%) patients with the carotid web; time to recurrence ranged from 1 to 97 months. Histopathology suggested a high probability of fibromuscular dysplasia. In the retrospective series, carotid webs were seen in 7/576 patients for a hospital-based-period prevalence of 1.2% (95% CI, 0.4%–2.5%). Two of these 7 patients had acute stroke in the vascular territory of the carotid web. CONCLUSIONS: A carotid web may contribute to recurrent ischemic stroke in patients with no other determined stroke mechanism. Intimal variant fibromuscular dysplasia is the pathologic diagnosis in most cases. The prevalence of carotid web is low, while the optimal management strategy remains unknown.
- 1 February 2014
- Published by Wolters Kluwer Health in Stroke
- Vol. 45 (suppl_1)
Abstract 7: Differential Effect of Baseline Cta Collateral Status on Clinical Outcomes in Patients Enrolled in the Ims-3 Trial
Introduction: In the IMS 3 trial, we test the hypothesis that a differential effect of endovascular therapy on clinical outcome will be most apparent in patients with severely ischemic but salvageable brain tissue (moderate collaterals on baseline CTA). Methods: Data is from patients in the IMS 3 study. Of 656 patients in the study, 306 patients had baseline CTA and 204 patients had M1 MCA +/_ intracranial ICA occlusion where baseline collaterals could be measured. Collateral status was assessed by consensus using 3 different scores and categorized as good, intermediate and poor. Details of the IMS 3 study protocol are described in the primary paper. Results: Of 204 patients, 138 received endovascular therapy (85.7% recanalized, 44.2% achieved 90-day mRS 0-2) and 66 received IV tPA only (57.1% recanalized, 36.4% achieved 90-day mRS 0-2). Proportion of patients with 90-day mRS 0-2 in good, intermediate and poor collateral categories between endovascular therapy and IV tPA across the 3 scores were: score 1(good: 56.5% vs. 41.7%, intermediate: 45.2% vs. 22.2%, poor: 18.4% vs. 23.5%); score 2 (good: 57.4% vs. 42.3%, intermediate: 40% vs. 23.1%, poor: 5.3% vs. 14.3%); score 3 (good: 51.6% vs. 42.3%, intermediate: 43.3% vs. 23.5%, poor: 20.6% vs. 18.8%). Using the van-Elteren test, a significant shift in 90-day mRS distribution in favor of endovascular therapy was noted only for subjects with intermediate collaterals. (p=0.01 for scores 1 and 2, Figure 1) Clinical outcome was poor with no differential effect of therapy in patients with poor collaterals. Conclusion: Patients with baseline intermediate collaterals have the highest likelihood of showing better clinical response to endovascular therapy. Future clinical trials testing IV tPA vs. endovascular therapy may have a higher likelihood of showing differential treatment effect if patients with baseline poor collaterals are excluded. Download figure
- 1 February 2014
- Published by Wolters Kluwer Health in Stroke
- Vol. 45 (suppl_1)
Abstract 7: Differential Effect of Baseline Cta Collateral Status on Clinical Outcomes in Patients Enrolled in the Ims-3 Trial
Introduction: In the IMS 3 trial, we test the hypothesis that a differential effect of endovascular therapy on clinical outcome will be most apparent in patients with severely ischemic but salvageable brain tissue (moderate collaterals on baseline CTA). Methods: Data is from patients in the IMS 3 study. Of 656 patients in the study, 306 patients had baseline CTA and 204 patients had M1 MCA +/_ intracranial ICA occlusion where baseline collaterals could be measured. Collateral status was assessed by consensus using 3 different scores and categorized as good, intermediate and poor. Details of the IMS 3 study protocol are described in the primary paper. Results: Of 204 patients, 138 received endovascular therapy (85.7% recanalized, 44.2% achieved 90-day mRS 0-2) and 66 received IV tPA only (57.1% recanalized, 36.4% achieved 90-day mRS 0-2). Proportion of patients with 90-day mRS 0-2 in good, intermediate and poor collateral categories between endovascular therapy and IV tPA across the 3 scores were: score 1(good: 56.5% vs. 41.7%, intermediate: 45.2% vs. 22.2%, poor: 18.4% vs. 23.5%); score 2 (good: 57.4% vs. 42.3%, intermediate: 40% vs. 23.1%, poor: 5.3% vs. 14.3%); score 3 (good: 51.6% vs. 42.3%, intermediate: 43.3% vs. 23.5%, poor: 20.6% vs. 18.8%). Using the van-Elteren test, a significant shift in 90-day mRS distribution in favor of endovascular therapy was noted only for subjects with intermediate collaterals. (p=0.01 for scores 1 and 2, Figure 1) Clinical outcome was poor with no differential effect of therapy in patients with poor collaterals. Conclusion: Patients with baseline intermediate collaterals have the highest likelihood of showing better clinical response to endovascular therapy. Future clinical trials testing IV tPA vs. endovascular therapy may have a higher likelihood of showing differential treatment effect if patients with baseline poor collaterals are excluded. Download figure